At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Aug 6, 2026 at 07:01 ET
Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt disease candidate gildeuretinol (ALK-001). The deal weds a promising but early-stage asset with no approved therapy today against Tarsus' existing retina capabilities, and top-line data is not expected until H2 2029. The acquisition is accretive to Tarsus' pipeline but adds significant execution risk and a long timeline.
- Upfront consideration: ~$450 million ($270M cash + $180M Tarsus common stock at $61.38/share).
- Milestones: up to $350 million upon regulatory approval and first commercial sale.
- Royalties: low single-digit tiered descending on gildeuretinol net sales.
- Phase 3 NORTHSTAR trial (enrolling ~230 patients) topline data expected H2 2029.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access